<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00485329</url>
  </required_header>
  <id_info>
    <org_study_id>ENZ-DER-002-IL</org_study_id>
    <nct_id>NCT00485329</nct_id>
  </id_info>
  <brief_title>Assessment of the Safety and Efficacy of DERMASTREAM™ - ENZYSTREAM™ System for the Treatment of Chronic Venous Ulcers</brief_title>
  <acronym>ENZ-DER-002-IL</acronym>
  <official_title>A Phase I/II Randomized, Double Blind, Placebo-Controlled Dose- Escalating Study, to Assess The Safety and Efficacy of Enzystream™ Debriding Solution (Papain) Applied by Dermastream™ Device for the Treatment of Lower Extremity Chronic Venous Ulcers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>EnzySurge</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>EnzySurge</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study objectives are to evaluate DermastreamTM - EnzystreamTM system safety, tolerability&#xD;
      and efficacy, as a potent method for debridement of nonhealing lower extremity chronic venous&#xD;
      ulcers patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a phase I/II prospective, randomized, double blind, placebo controlled, dose&#xD;
      escalating, three patient-group study, to evaluate the safety and efficacy of DermaStream™ -&#xD;
      EnzyStream™ System in non-healing lower extremity chronic venous ulcers patients. The&#xD;
      DermaStream™ - EnzyStream™ System will be evaluated during continues streaming of 3 different&#xD;
      doses of EnzystreamTM (papain based) solution given in an escalating order (15,000, 30,000&#xD;
      and 60,000 papain USP units/ml) up to 5 consecutive treatment days. Each treatment session&#xD;
      lasts for 6 hours. This study is a Multi center trial. It is anticipated that three (3) sites&#xD;
      will enroll subjects into this study. Overall, forty eight (48) patients will be recruited,&#xD;
      and randomly allocated to placebo or EnzyStream™ treatment in each study dose group prior to&#xD;
      EnzyStream™ administration. The ratio of drug to placebo treated patients will be 4;1, namely&#xD;
      12 patients will be administered with EnzyStream™ solution and 4 patients will be placebo&#xD;
      treated in each of the three respective EnzyStream™ dose groups. Treatment will start with&#xD;
      the lowest dose (15,000 papain USP units/ml) administered over a 6 hour period followed with&#xD;
      saline wash for an additional half an hour. The treatment dose will be increased to the next&#xD;
      highest dose, for the next patients group only following safety analysis, and the procedure&#xD;
      will be repeated.&#xD;
&#xD;
      The treatment period will be followed by a 3 month follow up period. During the follow up&#xD;
      period patients will be observed for every 2 weeks during the first month and once a month&#xD;
      (every 20 days) during the 2 additional months (allowing a time window of ± 3 days).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2007</start_date>
  <completion_date type="Actual">March 2009</completion_date>
  <primary_completion_date type="Actual">March 2009</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To demonstrate Dermastream-Enzystream safety</measure>
    <time_frame>Up to 88 days</time_frame>
    <description>Skin irritation score</description>
  </primary_outcome>
  <primary_outcome>
    <measure>To demonstrate Dermastream-Enzystream safety</measure>
    <time_frame>Up to 88 days</time_frame>
    <description>Severity and incidence of adverse events</description>
  </primary_outcome>
  <primary_outcome>
    <measure>To demonstrate Dermastream-Enzystream safety</measure>
    <time_frame>5 days</time_frame>
    <description>No deterioration in clinical laboratory parameters</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>•Assessment of changes in wound debridement status during treatment period</measure>
    <time_frame>Days 1-5</time_frame>
    <description>Change in non viable tissue area</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of wound closure</measure>
    <time_frame>Up to 88 days</time_frame>
    <description>Reduction of nonviable tissue area</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of wound closure</measure>
    <time_frame>Up to 88 days</time_frame>
    <description>Increase of granulation tissue area</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of wound closure</measure>
    <time_frame>Up to 88 days</time_frame>
    <description>Time (in days) for wound closure</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">48</enrollment>
  <condition>Lower Extremity Chronic Venous Ulcers</condition>
  <arm_group>
    <arm_group_label>Low dose papain</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ratio of drug to placebo treated patients will be 4:1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Medium dose papain</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ratio of drug to placebo treated patients will be 4:1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High dose papain</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ratio of drug to placebo treated patients will be 4:1</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Papain</intervention_name>
    <description>15,000 USP U/ml</description>
    <arm_group_label>Low dose papain</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Papain</intervention_name>
    <description>30,000 USP U/ml</description>
    <arm_group_label>Medium dose papain</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Papain</intervention_name>
    <description>60,000 USP U/ml</description>
    <arm_group_label>High dose papain</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patient must have a venous leg ulcer&#xD;
&#xD;
          2. Participants, either men or women are between 18 and 85 years of age.&#xD;
&#xD;
          3. Clinical presentation of venous insufficiency demonstrated by Doppler&#xD;
&#xD;
          4. Ankle-Brachial Index &gt; 0.7 by Doppler&#xD;
&#xD;
          5. Good palpable pulses in the Posterior Tibial and the Dorsalis Pedis arteries.&#xD;
&#xD;
          6. Wound present for at least 6 weeks prior to enrolment.&#xD;
&#xD;
          7. Wound length is in the range of: 1.5 - 7 centimeters.&#xD;
&#xD;
          8. The necrotic tissue area is at least 20% of wound area. (by clinical evaluation, i.e.,&#xD;
             inspection).&#xD;
&#xD;
          9. Wound San Antonio classification: Grade 1 or 2, Stage A or B.&#xD;
&#xD;
         10. Wound location: foot or calf, at a location where the device can be attached properly.&#xD;
&#xD;
         11. Participant understands the nature of the procedure and provides written informed&#xD;
             consent prior to any study procedure.&#xD;
&#xD;
         12. Women of child bearing potential must use adequate birth-control precautions.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Documented sensitivity to Papain, by medical history records.&#xD;
&#xD;
          2. Patients in need of surgical debridement.&#xD;
&#xD;
          3. Patients with general skin disorders (Psoriasis, Peniculitis ect) that might&#xD;
             deteriorate as a result of local trauma.&#xD;
&#xD;
          4. Patients with skin disorders unrelated to the ulcer that are presented adjacent to the&#xD;
             wound.&#xD;
&#xD;
          5. Pain sensation is completely absent (wound area is anesthetic).&#xD;
&#xD;
          6. Patients with renal failure. (Cr &gt; 2 mg/dl).&#xD;
&#xD;
          7. Patients with impaired hepatic function (ALT, AST or GGT 2-fold higher than normal&#xD;
             upper limit value).&#xD;
&#xD;
          8. Patients having Hypoalbuminemia: (Albumin &lt; 2gr/dl ).&#xD;
&#xD;
          9. Patients with general Immunological disorders that might deteriorate as a result of&#xD;
             local trauma.&#xD;
&#xD;
         10. Right-side congestive heart failure (CHF) with edema of legs: (NYHA class 2 or higher&#xD;
             see APPENDIX 5).&#xD;
&#xD;
         11. Participation in another clinical trial within 1 month prior to start of this study.&#xD;
&#xD;
         12. Subject unwilling or unable to comply with the requirements of the protocol&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Arie Bass, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assaf Harofe Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sami Nitezki, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rambam Health Care Campus</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hillel Yafe Medical Center</name>
      <address>
        <city>Hadera</city>
        <zip>38101</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rambam Medical Center</name>
      <address>
        <city>Haifa</city>
        <zip>35254</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Assaf Harofe Medical Center</name>
      <address>
        <city>Zriffin</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <link>
    <url>http://www.Enzysurge.com</url>
    <description>Related Info</description>
  </link>
  <verification_date>May 2010</verification_date>
  <study_first_submitted>June 10, 2007</study_first_submitted>
  <study_first_submitted_qc>June 11, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 12, 2007</study_first_posted>
  <last_update_submitted>May 24, 2010</last_update_submitted>
  <last_update_submitted_qc>May 24, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 25, 2010</last_update_posted>
  <keyword>Chronic Wounds, Venous Ulcers, Papain, Debridement, Continuous streaming</keyword>
  <keyword>DermaStream-EnzyStream</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Varicose Ulcer</mesh_term>
    <mesh_term>Ulcer</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

